Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Rehman

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
The Journal of Urology|April 18, 2007
Behavior of urothelial carcinoma with respect to anatomical locationJ W F Catto, D R Yates, I Rehman, et al.
Urology|December 15, 2004
Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot studyI Rehman, A R Azzouzi, J W F Catto, et al.
Journal of Biomedical Materials Research|March 24, 1998
Effect of heat treatment on pulsed laser deposited amorphous calcium phosphate coatingsF García, J L Arias, B Mayor, et al.
The Journal of Pathology|April 28, 2006
Evidence for the early onset of aberrant promoter methylation in urothelial carcinomaD Dhawan, F C Hamdy, I Rehman, et al.
International Journal of Rheumatic Diseases|June 2, 2020
A comparative study of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysisHideto Kameda, Eishi Uechi, Tatsuya Atsumi, et al.
British Journal of Cancer|July 29, 2004
S100A6 (Calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursorsI Rehman, S S Cross, A-R Azzouzi, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 16, 2020
Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III TrialStanley B Cohen, Sebastiao C Radominski, Hideto Kameda, et al.
Arthritis Research & Therapy|July 29, 2018
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapyStanley B Cohen, Rieke Alten, Hideto Kameda, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
The Journal of Urology|April 18, 2007
Behavior of urothelial carcinoma with respect to anatomical locationJ W F Catto, D R Yates, I Rehman, et al.
Urology|December 15, 2004
Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot studyI Rehman, A R Azzouzi, J W F Catto, et al.
Journal of Biomedical Materials Research|March 24, 1998
Effect of heat treatment on pulsed laser deposited amorphous calcium phosphate coatingsF García, J L Arias, B Mayor, et al.
The Journal of Pathology|April 28, 2006
Evidence for the early onset of aberrant promoter methylation in urothelial carcinomaD Dhawan, F C Hamdy, I Rehman, et al.
International Journal of Rheumatic Diseases|June 2, 2020
A comparative study of PF-06438179/GP1111 (an infliximab biosimilar) and reference infliximab in patients with moderate to severe active rheumatoid arthritis: A subgroup analysisHideto Kameda, Eishi Uechi, Tatsuya Atsumi, et al.
British Journal of Cancer|July 29, 2004
S100A6 (Calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursorsI Rehman, S S Cross, A-R Azzouzi, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 16, 2020
Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III TrialStanley B Cohen, Sebastiao C Radominski, Hideto Kameda, et al.
Arthritis Research & Therapy|July 29, 2018
A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapyStanley B Cohen, Rieke Alten, Hideto Kameda, et al.
Pageof 5